Cite
MLA Citation
Lana Zhovtis Ryerson et al.. “Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.” Neurology, vol. 93, 2019, p. . http://access.bl.uk/ark:/81055/vdc_100113948879.0x00005e
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lana Zhovtis Ryerson et al.. “Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.” Neurology, vol. 93, 2019, p. . http://access.bl.uk/ark:/81055/vdc_100113948879.0x00005e